261 - Personalized Phage Therapy

Saturday, October 19, 2024

3:15 PM – 4:30 PM US PT

Location: 408 B

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Manjunath Pai, PharmD

Professor of Clinical Pharmacy
University of Michigan
Ann Arbor, MI, United States
Mihnea Mangalea, PhD (he/him/his)

Bioinformatician
Centers for Disease Control and Prevention

Faculty(s)

Paul Bollyky, MD/PhD

Professor
Stanford University
Stanford, CA, United States
Ameneh Khatami, MBChB, MD, FRACP (she/her/hers)

Senior Lecturer/Paediatric Infectious Diseases Physician
University of Sydney/The Children's Hospital at Westmead
New York, NY, United States
Ghady Haidar, MD (he/him/his)

Associate Professor of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA, United States

Disclosure(s):

Manjunath P. Pai, PharmD: No financial relationships to disclose

Mihnea Mangalea, PhD: No financial relationships to disclose

Paul L. Bollyky, MD/PhD: No financial relationships to disclose

Ameneh Khatami, MBChB, MD, FRACP: No financial relationships to disclose

Ghady Haidar, MD: Allovir, Inc: Grant/Research Support (Terminated, May 6, 2024); AstraZenca: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Cystic Fibrosis Foundation: Grant/Research Support (Ongoing); Karius Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing); RedQueen Therapeutics: Advisor/Consultant (Ongoing); Regeneron, Inc: Grant/Research Support (Ongoing); SNIPR Biome: Advisor/Consultant (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the challenges and opportunities for bacteriophage therapy;
explain the role of therapeutic phage monitoring;
encourage the use of phage therapy for select complex cases.

Presentations:

3:15 PM – 3:40 PM US PT

Challenges and Opportunities for Bacteriophage Therapy
Speaker: Paul L. Bollyky, MD/PhD – Stanford University
3:40 PM – 4:05 PM US PT

Therapeutic Phage Monitoring: Application in Children
Speaker: Ameneh Khatami, MBChB, MD, FRACP (she/her/hers) – University of Sydney/The Children's Hospital at Westmead
4:05 PM – 4:30 PM US PT

Clinical Phage Therapy Today: Stories from the Bedside and Insights from the Lab
Speaker: Ghady Haidar, MD (he/him/his) – University of Pittsburgh School of Medicine